A Phase 2 interventional study of Seasonal influenza vaccine and MVA-NP+M1 in Influenza, sponsored by Barinthus Biotherapeutics. Terminated at 5 sites in United Kingdom. Open to participants aged 65 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-11-23.
Sponsored by Barinthus Biotherapeutics · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 151 studies in Influenza, Human with a site in United Kingdom — 8 open to participants now, 13 under way, 4 of them phase 3. Influenza, Human · United Kingdom.
Among the 151 studies in Influenza, Human with a site in United Kingdom, this one is the 23rd largest by enrollment of the 123 interventional ones that give a count, is one of 6 that started in 2017, is one of 38 in phase 2, and was the 105th registered.
2,361 studies on the registry are indexed under Influenza, Human; 186 are open to participants now.
Browse Influenza, Human studies →8 of the 151 studies in Influenza, Human with a site in United Kingdom are open now. Recruiting first, the newest first:
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · Sites in United Kingdom, United States, Argentina and 3 more countries
Ages 12+
Imperial College London · Sites in United Kingdom
Ages 18–55 · Healthy volunteers
Region Örebro County · Sites in United Kingdom, Denmark, Sweden
Ages 18+
Hvivo · Sites in United Kingdom
Ages 18–55 · Healthy volunteers
AstraZeneca · Sites in United Kingdom, United States, Argentina and 36 more countries
Ages 18+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 124 Influenza, Human studies recruiting now, 67 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 69 take healthy volunteers.
This study: 65 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
151 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 30 · Phase 2 43 · Phase 3 21 · Phase 4 16
First in 2003; this study’s year is marked. 6 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 862 is above the median of 228 across 1,959 interventional studies indexed under Influenza, Human.
Median enrollment 129 across the 123 interventional studies, 574 across the 28 observational. Of the 131 that completed or were terminated, 47 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
90 of 151 have an industry lead sponsor. The 10 most frequent:
Barinthus Biotherapeutics is the lead sponsor of 10 studies on the registry; none are open to participants now.
Barinthus Biotherapeutics has 3 studies filed under Influenza, Human — fewer than ten, so there is no comparison to draw.
5 of the studies in Influenza, Human with a site in United Kingdom that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07496450Phase 3ModernaTX, Inc.A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults | 2027-01-28 |
| NCT07159763Phase 3Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)A Study to Evaluate the Safety and Efficacy of MK-1406/CD388 for Prevention of Influenza (MK-1406-005/CD388.SQ.3.06) | 2027-07-02 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
| NCT07503405Traws Pharma, Inc.Phase 2a Study of the Efficacy and Safety of TRX-100 in a Human Influenza A Challenge Model | 2026-11 |
| NCT07225959Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)A Study of Annual Doses of MK-1406/CD388 in Healthy Adults (MK-1406-006/CD388.SQ.2.07) | 2027-07-31 |
Add all 5 to your calendar (.ics) → With an account.
Among the 151 studies in Influenza, Human with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A Phase IIb randomised, participant-blinded, placebo-controlled, multi-centre phase IIb efficacy study in 2030 volunteers aged 65 and over. The study will assess the safety and efficacy of the co-administration of a viral vectored vaccine, MVA- NP+M1, and the annual recommended licensed inactivated influenza vaccine (IIV). Within the main cohort 100 participants will be recruited to an immunology sub-cohort.
The efficacy of current seasonal influenza vaccines is limited in the face of antigenic mismatch between circulating viral strains and those in the given vaccine. Additionally vaccination in older adults, a major target group for vaccination, prevents laboratory-confirmed influenza in only 30-40% compared to 70-90% in young adults. The hypothesis in this Phase IIb efficacy study is that a new vaccine MVA-NP+M1 with licensed inactivated influenza vaccine (IIV) in the older age group will be able to induce immune responses that protect individuals against influenza illness, severity of symptoms and reduce viral shedding, thereby increasing the protection conferred by seasonal influenza vaccine alone. A total of 2030 participants who are 65 years of age or over and eligible for annual seasonal influenza vaccination and provide informed consent will be recruited to the study. Potential volunteers will be mailed an invitation to take part by their GPs or recruited by local advertisements. Participants will be randomised to receive either MVA- NP+M1 with licensed IIV or saline placebo with licensed IIV. In the first 28 days after vaccination, participants will record adverse events using an electronic or paper diary. The participants will be contacted by telephone 1 day and 7 days post-vaccination to enquire about any serious adverse events and support follow up. During influenza season participants will record weekly whether or not they have had an influenza like illness (ILI). For every ILI episode experienced, the participants will record the severity of their symptoms daily. Among the participants, a total of 100 volunteers (50 in each group) will be recruited into an immunology sub-cohort. They will have blood samples collected on the day of vaccination, 1 week, 3 weeks and 26 weeks post-vaccination for monitoring of laboratory adverse events and immunogenicity purposes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Two vaccinations will be administered: Seasonal influenza vaccine \& MVA-NP+M1
Drug: Seasonal influenza vaccine · Drug: MVA-NP+M1
Two vaccinations will be administered: Seasonal influenza vaccine \& sodium chloride
Drug: Seasonal influenza vaccine · Drug: Sodium chloride
Seasonal influenza vaccine
Also known as: Quadrivalent Influenza Vaccine
Drug page: MVA-NP+M1Studies of MVA-NP+M1MVA-NP+M1 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Trial vaccine
Saline placebo
Number of days with moderate or severe influenza-like symptoms
Throughout the influenza season, self-reported symptoms recorded using electronic or paper diaries
Time frame: 6-7 months
Incidence of influenza-like-illness
Throughout the influenza season, self-reported symptoms recorded using electronic or paper diaries
Time frame: 6-7 months
Severity of influenza-like symptoms
Throughout the influenza season, self-reported symptoms recorded using electronic or paper diaries
Time frame: 6-7 months
Duration of influenza-like-illnes
Throughout the influenza season, self-reported symptoms recorded using electronic or paper diaries
Time frame: 6-7 months
Occurrence of GP consultations from respiratory illness
Throughout the influenza season - self-reported and Medical Records
Time frame: 6-7 months
Occurrence of hospitalisations and deaths due to respiratory illness
Throughout the influenza season - self-reported and Medical Records
Time frame: 6-7 months
Occurrence of solicited local and systemic reactogenicity signs and symptoms for 7 days following vaccination
Self-reported symptoms recorded using electronic or paper diaries
Time frame: Day 0-7
Occurrence of serious adverse events during the whole study duration
Telephone calls on Day 1-3, day 7-9 and every 3-4 weeks throughout volunteers' participation in the trial
Time frame: 6-7 months
Occurrence of unsolicited adverse events for 28 days following vaccination
Self-reported symptoms recorded using electronic or paper diaries
Time frame: Day 0-28
Frequency of influenza-specific T-cells measured by IFNg ELISpot
To assess the immunogenicity of MVA-NP+M1 in combination with the recommended licensed inactivated influenza vaccine in adults aged 65 years and above
Time frame: 6-7 months
Geometric mean titre of influenza-specific neutralising antibodies
To assess the immunogenicity of MVA-NP+M1 in combination with the recommended licensed inactivated influenza vaccine in adults aged 65 years and above
Time frame: 6-7 months
Breadth of influenza-specific T-cells and antibodies
To assess the immunogenicity of MVA-NP+M1 in combination with the recommended licensed inactivated influenza vaccine in adults aged 65 years and above
Time frame: 6-7 months
Estimated frequency of influenza infection using historical data on the proportion of ILIs that is caused by influenza virus infection.
To explore novel clinical endpoints for future Phase III efficacy trials of influenza vaccines
Time frame: 6-7 months
Plan to share: No
Ran from Oct 2017 to primary completion in Oct 2018, 12 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in May 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: MVA-NP+M1
Barinthus Biotherapeutics